Search
Abetimus
go.drugbank.com/drugs/DB06662InvestigationalAbetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Dilmapimod
go.drugbank.com/drugs/DB12140InvestigationalDilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). … Methotrexate (common treatment for RA patients) also has potential liver toxicity.}
Categories: Heterocyclic Compounds, 1-RingMolsidomine
go.drugbank.com/drugs/DB09282ApprovedWithdrawnInterestingly, it is being studied as being a preventive measure in cerebral infarction [A31932].
Categories: Heterocyclic Compounds, 1-RingProducts: MOLSIDOMIN 8 RET 1A PHARMA, MOLSIDOMIN 2 HEUMANNCertoparin
go.drugbank.com/drugs/DB09261ApprovedCertoparin is part of the heparins of low molecular weight that presents high activity against the coagulation factor Xa. It is normally used to prevent deep venous thrombosis.
Digitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnA cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexBuserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalBuserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).
Products: Suprefact Depot 2 Months, SUPREFACT INJECTABLE 1 mg/mlDarbepoetin alfa
go.drugbank.com/drugs/DB00012ApprovedInvestigationalHuman erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Products: ARANESP 150UG ILO FER ANS, ARANESP 500UG ILO IN FERSR-123781A
go.drugbank.com/drugs/DB05361InvestigationalSR-123781A is a synthetic hexadecasaccharide Factor IIa and Xa antagonist. It is under investigation by Sanofi-Aventis and Organon for the treatment of thrombosis and acute coronary syndromes (ACS).
Deslanoside
go.drugbank.com/drugs/DB01078ApprovedDeacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.
Synonyms: (3β,5β,12β)-3-{[β-D-glucopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide, 3-[(O-β-D-glucopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3β,5β,12β-card-20(22)-enolideInternational brands: Cedilanid-DSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Cytochrome P-450 Substrates